Note: You clicked on an external link, which has been disabled in order to keep your shopping session open.
|Tested species reactivity||Human|
|Published species reactivity||Human|
|Host / Isotype||Mouse / IgG2b|
|Immunogen||Activated human peripheral blood mononuclear cells.|
|Storage buffer||tissue culture supernatant with 0.7% BSA|
|Contains||0.1% sodium azide|
|Storage Conditions||4° C|
|Tested Applications||Dilution *|
|Immunohistochemistry (Paraffin) (IHC (P))||Assay dependent.|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
HLA DR, like other MHC class II molecules, is a transmembrane glycoprotein composed of an alpha chain (36 kDa) and a beta chain (27 kDa). It is expressed primarily on antigen presenting cells such as B lymphocytes, monocytes, macrophages, thymic epithelial cells and activated T lymphocytes. Three loci, DR, DQ and DP, encode the major expressed products of the human class II region. The human MHC class II molecules bind intracellularly processed peptides and present them to T-helper cells. They therefore have a critical role in the initiation of the immune response.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Appearance of tissue transglutaminase in astrocytes in multiple sclerosis lesions: a role in cell adhesion and migration?
MA1-35420 was used in immunohistochemistry to investigate the role of tissue transglutaminase in astrocytes in multiple sclerosis lesions
|van Strien ME,Drukarch B,Bol JG,van der Valk P,van Horssen J,Gerritsen WH,Breve JJ,van Dam AM||Brain pathology (Zurich, Switzerland) (21:44)||2011|
Endometrial atypical hyperplasia with clear cell change spreading throughout the endometrium.
MA1-35420 was used in immunohistochemistry to report on a case of endometrial atypical hyperplasia with clear cell change spreading throughout the endometrium
|Nakashima N,Nagasaka T,Murakami S,Fukatsu T,Satake T||Annals of diagnostic pathology (7:381)||2003|
Identification of new MHC-restriction elements for presentation of the p210(BCR-ABL) fusion region to human cytotoxic T lymphocytes.
MA1-35420 was used in blocking or activating experiment to investigate the immune response against the p210(BCR-ABL) fusion region in chronic myelogenous leukemia
|Sun JY,Senitzer D,Forman SJ,Chatterjee S,Wong KK||Cancer immunology, immunotherapy : CII (52:761)||2003|
Clone P2-beta-3; DR-16; DRB1; DRw10; DW2.2/DR2.2; FLJ75017; FLJ76359; HLA class II histocompatibility antigen, DR-1 beta chain; HLA class II histocompatibility antigen, DRB1-15 beta chain; HLA class II histocompatibility antigen, DRB1-16 beta chain; HLA class II histocompatibility antigen, DRB1-3 chain; HLA-DR1B; HLA-DRB; HLA-DRB1*; human leucocyte antigen DRB1; lymphocyte antigen DRB1; MHC class II antigen; MHC class II antigen DRB1*15; MHC class II antigen DRB1*16; MHC class II antigen DRB1*3; MHC class II HLA-DR beta 1 chain; MHC class II HLA-DR-beta cell surface glycoprotein; MHC class II HLA-DRw10-beta; SS1; XXbac-BPG161M6.1
DRB1; DRw10; HLA-DR1B; HLA-DRB; HLA-DRB1; HLA-DRB2; SS1